A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis.

Purpose: Compare safety, tolerability, efficacy of BAF312 vs. placebo on MRI lesions in relapsing-remitting MS.

• Must be 18-55 y/o, male or female
• Must be diagnosed with relapsing remitting multiple sclerosis, with at least one documented relapse during the last year, or two documented relapses during the last two years, or have a positive Gadolinium-enhanced MRI scan during screening.
• Must have an EDSS score of 0-5.0
• Must be able to perform and complete all protocol visits and procedures.

A double-blind, randomized, multi-center, placebo controlled, parallel-group tudy comparing the efficacy and safety of 1.25mg (FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis.

Purpose: The purpose of this study in patients with primary progressive multiple sclerosis (PPMS) is to evaluate whether FTY720 is effective in delaying MS disability progression in the absence of relapses compared to placebo.

• Male or female, 25-60 y/o
• EDSS score of 3.5-6.0
• Documented diagnosis of Primary Progressive Multiple Sclerosis
• One year of disease progression
• Two of the following:
  • a) positive brain MRI (nine T2 lesions or four or more T2 lesions with positive visual evoked potential);
  • b) positive spinal cord MRI (two focal T2 lesions);
  • c) positive CSF.
• Central review of the evidence will be required to randomization. Patients who meet all three criteria (a, b & c) do not need to be submitted for central review.

A Combination trial of copaxone plus Estriol in relapsing remitting multiple sclerosis.

Purpose: The purpose of this two year study is to determine:

1. If the use of oral estriol in combination with Copaxone injection is safe;
2. If the use of combination treatment causes a decrease in relapse rates;
3. If there is more rapid improvement on brain MRI withi the combination treatment; and
4. If there is an improvement in disability measures with the combination.

• Only Females 18 to 50 years old.
• Relapse/Remitting MS..
• EDSS (expanded disability status scale) 0 to 4.5.
• Not on any other therapy for MS.

It is hoped that patients taking Estriol in combination with Copaxone injections will do better with their MS. We hope the information learned from this study will benefit other individuals with MS in the future.

• 18 to 55 years old
• Relapsing/Remitting MS
• EDSS score: 0 to 5.5 (able to walk 100 meters without aids)
• Must be available for clinic visits for the duration of the study